Figure 1. Pancuronium (0.01–1.0 mg/kg intravenous) potentiates vagally induced bronchoconstriction in the lungs (closed squares; left) but inhibits acetylcholine-induced bronchoconstriction (open triangles). In the heart, pancuronium inhibits bradycardia induced by vagal stimulation (closed squares; right) and by intravenous acetylcholine equally (open triangles). Data are expressed as the mean+/-SEM of the ratio of the response to vagal stimulation or intravenous acetylcholine in the presence of pancuronium to the response in the absence of pancuronium. In the absence of pancuronium the increase in pulmonary inflation pressure with vagal stimulation was 34.7+/-6.4 mmH2O, the increase in pulmonary inflation pressure with intravenous acetylcholine was 39.0 +/-9.0 mmH2O. These responses were not significantly different from each other. In the heart, in the absence of pancuronium, the decrease in heart rate with vagal stimulation was 83.6+/-22.3 beats/min, the decrease in heart rate with intravenous acetylcholine was 91.7+/-28.6 beats/min. These responses also were not significantly different from each other (n = 4).
